A Explorative Pilot Study to Gain Insights for a New Senior Milk Powder
Xuanwu Pilot: A Prospective, Interventional, Single-arm, Before-and-after Explorative Pilot to Gain Insights on Gastrointestinal and Related Benefits of the New Senior Milk Powder
1 other identifier
interventional
30
1 country
1
Brief Summary
The purpose of this interventional, single-arm pilot study aimed to evaluate the new product that newly developed contains a mixture of prebiotics and probiotics to gain insights of GI function acceptance, microbiological composition and related benefits before and after study product consumption in population aged between 50-70 years. This project also serves the purpose of formulating conceptual hypothesis and directions of exploration for future research. The main questions it aims to answer are:
- 1.Microbiological change from stool samples collected at baseline and in the days after study product usage
- 2.Gastrointestinal function and acceptance assessed during the study period
- 3.Health related outcomes assessed via wearable device
- 4.Any safety events
- 5.Take study product
- 6.Visit the study site
- 7.Collect the stool sample
- 8.Record daily gastrointestinal tolerance and health data
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable healthy-volunteers
Started Feb 2025
Shorter than P25 for not_applicable healthy-volunteers
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 1, 2024
CompletedFirst Posted
Study publicly available on registry
October 17, 2024
CompletedStudy Start
First participant enrolled
February 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 14, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 14, 2025
CompletedJuly 25, 2025
July 1, 2025
1 month
October 1, 2024
July 24, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Gastrointestinal (GI) function Questionnaire
Gastrointestinal symptoms assessed the tolerance of product via the Incidence of gastrointestinal discomfort
from baseline (0 day) to the end of treatment at 28 days
Secondary Outcomes (1)
Microbiological analysis
from baseline to the end of study at 28 days
Other Outcomes (1)
Sleep quality analysis from wearable device
from baseline (0 days) to end of treatment at 28 days
Study Arms (1)
Milk Powder (study product) usage group
EXPERIMENTALInvestigational Product Participants in this arm will need to take 2 times every day from baseline visit to 28 days.
Interventions
Take the elderly milk power 2 times every day up to 28 days
Eligibility Criteria
You may qualify if:
- Age 50-70 years (bounds included)
- Body Mass Index (BMI) between 18.5 (bound included) and 30 (bound excluded) kg/m2.
- Ability to comply with the protocol and assessment window:
- Product intake according to instructions.
- Willing to collect, store, deliver stool sample according to instructions.
- Willing to adhere to instructions and restrictions during entire study period\*:
- No probiotic supplementations or products supplemented with probiotics.
- No dietary fiber supplements.
- No medications may modify gastrointestinal function.
- Fluency in speaking, reading and writing in mandarin.
- Capability of the subject to install and use the secure study platform on the smartphone during entire study period.
- Written informed consent. \*Overruled in case of medical needs.
You may not qualify if:
- Known / Existing gastrointestinal diseases or disorders diagnosed by a physician that may interfere with study.
- Known / Existing milk protein allergies, lactose intolerance or other allergies to product ingredients.
- Known / Existing immune diseases or disorders diagnosed by a physician that may interfere with study.
- Use of any medication may modify gastrointestinal function: tricyclic antidepressants, SSRIs/antidepressants, opioids, ACE inhibitor, bate sympathomimetics, systemic antibiotics, intestinal antiseptics, anti-inflammatory medicines (including nonsteroidal anti-inflammatory drugs \[NSAIDs\] and aspirin), anti-histamines, steroids, corticosteroids, laxatives, anti-diarrhoea medication, prokinetics/dopamine-antagonists, metformin, statins, or any other stomach medication (including proton pump inhibitor \[PPIs\], antiacids, and antihistamine2 blockers) within 8 weeks prior to enrolment.
- Consumption of probiotic supplementations or products supplemented with probiotics within 4 weeks prior to enrolment.
- Subject following a special diet, including but not limited to vegan diet, ketogenic diet, low fiber diet, thickening diet etc.
- Incapability to comply with protocol as per the judgement of the investigator.
- Participation in any other studies involving investigational or marketed products concomitantly or 2 weeks prior to enrolment.
- Employees and/or children/family member or relatives of employees of Danone or the participating site.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Danone Nutricialead
Study Sites (1)
Lisheng Scientific Lab
Shanghai, Shanghai Municipality, China
Study Officials
- PRINCIPAL INVESTIGATOR
Charlie Zhang, MD
Lisheng Scientific Lab
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 1, 2024
First Posted
October 17, 2024
Study Start
February 7, 2025
Primary Completion
March 14, 2025
Study Completion
March 14, 2025
Last Updated
July 25, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share